Home / Health / Amgen’s Ovarian Cancer Treatment Fails To Meet Endpoints

Amgen’s Ovarian Cancer Treatment Fails To Meet Endpoints

Amgen Inc. pronounced Tuesday that a late-stage hearing of a ovarian cancer treatment, trebananib, unsuccessful to significantly urge studious survival.

The Phase 3 investigate had sought to weigh a reserve and efficiency of a treatment, taken in multiple with chemotherapy drug paclitaxel, in women with ovarian cancer. Amgen pronounced Tuesday that the…

Article source: http://online.wsj.com/article/SB11550989027533334316504580256474279484544.html

Scroll To Top